Literature DB >> 19244612

A structural rationale for selective stabilization of anti-tumor interactions of 14-3-3 proteins by cotylenin A.

Christian Ottmann1, Michael Weyand, Takeshi Sassa, Takatsugu Inoue, Nobuo Kato, Alfred Wittinghofer, Claudia Oecking.   

Abstract

Cotylenin A, a fungal metabolite originally described as a cytokinin-like bioactive substance against plants shows differentiation-inducing and anti-tumor activity in certain human cancers. Here, we present the crystal structure of cotylenin A acting on a 14-3-3 regulatory protein complex. By comparison with the closely related, but non-anticancer agent fusicoccin A, a rationale for the activity of cotylenin A in human cancers is presented. This class of fusicoccane diterpenoids are possible general modulators of 14-3-3 protein-protein interactions. In this regard, specificities for individual 14-3-3/target protein complexes might be achieved by varying the substituent pattern of the diterpene ring system. As the different activities of fusicoccin A and cotylenin A in human cancers suggest, hydroxylation of C12 might be a sufficient determinant of structural specificity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19244612     DOI: 10.1016/j.jmb.2009.01.005

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  17 in total

1.  Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling.

Authors:  Manuela Molzan; Benjamin Schumacher; Corinna Ottmann; Angela Baljuls; Lisa Polzien; Michael Weyand; Philipp Thiel; Rolf Rose; Micheline Rose; Philipp Kuhenne; Markus Kaiser; Ulf R Rapp; Jürgen Kuhlmann; Christian Ottmann
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

Review 2.  14-3-3 proteins as signaling integration points for cell cycle control and apoptosis.

Authors:  Alexandra K Gardino; Michael B Yaffe
Journal:  Semin Cell Dev Biol       Date:  2011-09-14       Impact factor: 7.727

Review 3.  14-3-3 proteins as potential therapeutic targets.

Authors:  Jing Zhao; Cheryl L Meyerkord; Yuhong Du; Fadlo R Khuri; Haian Fu
Journal:  Semin Cell Dev Biol       Date:  2011-10-01       Impact factor: 7.727

4.  Structure of a 14-3-3σ-YAP phosphopeptide complex at 1.15 A resolution.

Authors:  Benjamin Schumacher; Malgorzata Skwarczynska; Rolf Rose; Christian Ottmann
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-08-21

5.  Multisite phosphorylation of 14-3-3 proteins by calcium-dependent protein kinases.

Authors:  Kirby N Swatek; Rashaun S Wilson; Nagib Ahsan; Rebecca L Tritz; Jay J Thelen
Journal:  Biochem J       Date:  2014-04-01       Impact factor: 3.857

Review 6.  Taspase1: a 'misunderstood' protease with translational cancer relevance.

Authors:  D Wünsch; A Hahlbrock; S Jung; T Schirmeister; J van den Boom; O Schilling; S K Knauer; R H Stauber
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

7.  Analysis of Interactions Stabilized by Fusicoccin A Reveals an Expanded Suite of Potential 14-3-3 Binding Partners.

Authors:  Ananya Sengupta; Josue Liriano; Brian G Miller; James H Frederich
Journal:  ACS Chem Biol       Date:  2020-01-29       Impact factor: 5.100

8.  Fusicoccin Activates KAT1 Channels by Stabilizing Their Interaction with 14-3-3 Proteins.

Authors:  Andrea Saponaro; Alessandro Porro; Antonio Chaves-Sanjuan; Marco Nardini; Oliver Rauh; Gerhard Thiel; Anna Moroni
Journal:  Plant Cell       Date:  2017-09-29       Impact factor: 11.277

Review 9.  From plant physiology to pharmacology: fusicoccin leaves the leaves.

Authors:  Lorenzo Camoni; Sabina Visconti; Patrizia Aducci; Mauro Marra
Journal:  Planta       Date:  2018-11-22       Impact factor: 4.116

Review 10.  14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases.

Authors:  F Sanders Pair; Talene A Yacoubian
Journal:  Trends Pharmacol Sci       Date:  2021-01-28       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.